GeoVax Labs (NASDAQ:GOVX) Releases Earnings Results, Beats Estimates By $15.60 EPS

GeoVax Labs (NASDAQ:GOVX) issued its quarterly earnings results on Thursday. The company reported ($10.56) EPS for the quarter, beating analysts’ consensus estimates of ($26.16) by $15.60, FiscalAI reports.

GeoVax Labs Price Performance

Shares of NASDAQ GOVX traded down $0.30 during mid-day trading on Friday, reaching $1.74. 65,784 shares of the company’s stock were exchanged, compared to its average volume of 76,692. The firm has a market capitalization of $539,400.00, a price-to-earnings ratio of -0.15 and a beta of 3.85. GeoVax Labs has a 52 week low of $1.57 and a 52 week high of $275.88. The firm has a 50-day moving average price of $6.91 and a two-hundred day moving average price of $27.58.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on GOVX shares. Noble Financial reaffirmed an “outperform” rating on shares of GeoVax Labs in a research note on Tuesday, September 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of GeoVax Labs in a research report on Thursday, October 15th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $3,600.00.

About GeoVax Labs

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer. The company’s technology platform is based primarily on modified vaccinia Ankara (MVA) and virus-like particle (VLP) vaccine technologies, which are designed to generate broad and durable immune responses. GeoVax’s pipeline has included GEO-CM04S1, a multivalent COVID-19 vaccine candidate intended to address emerging coronavirus variants, as well as investigational vaccines for HIV, hemorrhagic fever viruses such as Ebola and Marburg, and other infectious diseases.